Esperion Therapeutics, Inc. · NASDAQ:ESPR
Esperion Therapeutics — Q2 2025 Earnings Presentation
20 slides from Esperion Therapeutics's earnings presentation, Aug 5, 2025
Slide 1: Q2 2025 Earnings Presentation
Q2 2025 Earnings Presentation August 5, 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved.
Slide 2: Forward-looking Statements & Disclosures
Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational
Slide 3: CEO Commentary
CEO Commentary “Our second quarter performance highlights the strength of our commercial execution, growing adoption of our therapies, and continued progress in protecting and expanding the long-term value of our portfolio. Our first quarter of operating income from ongoing business marks a key Shel
Slide 4: Q2 2025: Delivering Strong Momentum
Q2 2025: Delivering Strong Momentum Q2 TOTAL REVENUE Q2 U.S. NET PRODUCT SALES $82.4M $40.3M +12% growth +42% growth +10% First Quarter of >28,000 Retail Prescription Operating Income from Healthcare Providers Equivalents Q/Q Ongoing Business Writing Scripts 4 © 2025 Esperion. All Rights Reserved –
Slide 5: Expanded Core Marketing Efforts to Reach Statin-Intolerant Patients
Expanded Core Marketing Efforts to Reach Statin- Intolerant Patients Can’t take a statin? Make NEXLIZET happen! • Over 650,000 visits to our consumer statin intolerance website in Q2 • More than 600,000 click throughs to our HCP statin intolerance site in Q2 Strong engagement underscores the impact
Slide 6: Strengthening Access and Driving Growth
Strengthening Access and Driving Growth Resulted in: Expanded payer coverage and • 10% increase in total retail prescription equivalents vs. Q1 reduced prior authorization 2025 requirements • Now over 28,000 total HCPs • 23% of prescriptions written by physicians with only digital Enhanced reimburse
Slide 7: Award-Winning Consumer Campaign: Lipid Lurkers
Award-Winning Consumer Campaign: Lipid Lurkers • Tackling the silent threat of high cholesterol through a bold, creative lens • Introduces Lipid Lurkers – mischievous characters that personify the hidden dangers of LDL-C • Educates and empowers patients to take the next steps after statins • Drives
Slide 8: Advancing Growth Through Strategic Execution
Advancing Growth Through Strategic Execution Consumer Growth Drivers and IP Protection and Pipeline Expansion: Awareness Strategic Outlook Legal Progress Novel ACLY Biology Expansion • Launch consumer television • Continued momentum • Reached settlements with • Advancing IND-enabling ad on connected
Slide 9: Strategic Partnerships Driving Global Reach
Strategic Partnerships Driving Global Reach Approved in Maximizing Global Reach Across Key Regions 40 countries Japan Australia & Canada globally Europe Asia & South America Israel New Zealand Otsuka Pharmaceutical Co., Partner Daiichi Sankyo Europe Daiichi Sankyo Co., Ltd. Neopharm Israel CSL Seqir
Slide 10: International Growth Continues at Strong Pace
International Growth Continues at Strong Pace 600,000 ~555,000 patients through May’25 500,000 400,000 300,000 200,000 100,000 - Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, the Netherlands. 10 ©
Slide 11: Pipeline Advancement
cSPERION Pipeline Advancement
Slide 12: Proven Science, Innovative Pipeline
Proven Science, Innovative Pipeline Innovative Portfolio & Pipeline LEAD PRECLINICAL CLINICAL APPROVED / PRODUCT/PROGRAM EXPLORATORY LEAD ID OPTIMIZATION DEVELOPMENT DEVELOPMENT COMMERCIAL MILESTONES Cardiovascular Disease (LDL-C lowering / CV Risk reduction) NEXLETOL® Approved 2020 bempedoic acid E
Slide 13: High Unmet Need Driving Significant Market Opportunity
High Unmet Need Driving Significant Market Opportunity PSC: A Rare and Progressive Liver Disease >$1B Annual Market Opportunity Estimate Diagnosed Prevalence of PSC • No approved therapies with proven efficacy to cure or halt PSC progression 30K3-5 • Potential Orphan Drug Designation & Fast Track Ap
Slide 14: Financial Update
Financial Update Ben Halladay, Chief Financial Officer
Slide 15: Exceptional Second Quarter Drives Path to Profitability
Exceptional Second Quarter Drives Path to Profitability First Quarter of Operating Income from Supports Transition to Sustainable Profitability Ongoing Business in Company’s History Beginning in Q1 2026 COLLABORATION REVENUE TOTAL REVENUE U.S. NET PRODUCT SALES $42.1M $82.4M $40.3M -7% decrease +12%
Slide 16: Cash and 2025 Guidance
Cash and 2025 Guidance Key Financial Data Cash & Cash Equivalents FY 2025 R&D Guidance $55 – 65 M $160 – 170 M $86.1M FY 2025 SG&A Guidance FY 2025 OpEx Guidance1 $215 – 235 M 1. Includes ~$15 million of non-cash stock-based compensation expense 16 © 2025 Esperion Therapeutics, Inc. All rights reser
Slide 17: Strong Prescription Demand and Increasing Physician Adoption Continue to Drive Durable Revenue Growth
Strong Prescription Demand and Increasing Physician Adoption Continue to Drive Durable Revenue Growth Quarterly Franchise RPE Trend Weekly Franchise RPE Trend1 240,000 20,000 220,000 18,000 200,000 +10% 16,000 180,000 160,000 14,000 140,000 12,000 120,000 10,000 100,000 8,000 80,000 6,000 60,000 4,0
Slide 18: Important Safety Information
Important Safety Information
Slide 19: NEXLETOL Important Safety Information
NEXLETOL® (bempedoic acid) Important Safety Information • NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred. • Hyperuricemia: NEXLETOL may increase b
Slide 20: NEXLIZET Important Safety Information
NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information • NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been re
Esperion Therapeutics — Q2 2025 Earnings Presentation on 6ix